Clinical Trial to Evaluate the Visual Performance of Two Monofocal Intraocular Lenses

• Patient informed of the consequences and constraints of the protocol and who has given his/her written informed consent;
• Patients of any gender, aged 50 to 90 years;
• Senile cataract in at least 1 eye;
• Assured follow-up examinations;
• Healthy eyes besides clinically significant cataract
• Biometry measurement/cataract density compatible with the IOLMaster evaluation.

Post-operative inclusion criteria:

• IOL implanted in the capsular bag;
• The IOL model (CT LUCIA 601PY or Acrysof IQ SN60WF) has been implanted;
• No intraoperative complications; no damaged capsular bag, no intraocular hemorrhage; no can opener rhexis.

Exclusion Criteria:

• • Patients unable to meet the limitations of the protocol or likely of non-cooperation during the trial;

    • Patients whose freedom is impaired by administrative or legal order;
    • Current participation in another drug or device investigation;
    • Allergy to heparin
    • Monophthalmic patient
    • Ocular disorders, other than cataract, that could potentially cause future acuity loss to a level of 0.20 logMAR (best-corrected) or worse the operated eye
    • Any anterior segment pathology that could significantly affect outcomes (e.g. chronic uveitis, iritis, corneal dystrophy, etc.)
    • Diabetic retinopathy
    • Traumatic cataract
    • Aniridia
    • Microphthalmus
    • Amblyopia
    • Degenerative visual disorders (e.g. macular degeneration, optic nerve atrophy, or retinal disorders)
    • Patient expected to require retinal laser treatment before the end of the follow-up
    • Previous intraocular and corneal surgery
    • Expected postop. astigmatism greater than 1 D
    • Any type of corneal disorder
    • Dementia
    • Diabetes mellitus
    • Pseudoexfoliation syndrome (PXF)
    • Glaucoma or IOP higher than 24mmHg under ocular hypertension treatment
    • Any other pathology or condition presenting, according to the investigator opinion, a risk for the patient